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The analysis of body-burden concentration for 2,3,7,8-tetra 
chloro- dibenzo-p-dioxin (2,3,7,8-TCDD) exposure in humans has 
utilized adipose tissue as the matrix of choice. A more practical and 
less invasive method would be necessary for a large-scale study. The 
use of serum is a logical alternative. We have attempted a number of 
methods in the analysis of serum for 2,3,7,8-TCDD content. We describe 
an analytical method to measure 2,3,7,8-TCDD in human serum by using a 
highly specific cleanup procedure and high-resolution gas 
chromatography/high resolution mass spectrometry. The 2,3,7,8-TCDD is 
quantified by the isotope dilution technique with 
1 
13 
t C12]-2,3,7,8-TCDD as the internal standard. The method is 
modified for analyzing 50g and 10g serum samples. The analytical 
accuracy of the method is demonstrated by analyzing spiked samples. The 
method is shown to be unaffected by a number of potentially interfering 
compounds. A series of quality control materials is used to verify 
system performance. For 200g samples containing 25.8 parts 
per-quadrillion of native 2,3,7,8-TCDD, a coefficient of variation (CV) 
of 13% is observed (n = 20). For 10g samples from a pool fortified with 
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Int rocLuct: ion 
Dioxin has often been given the dubious distinction of being 
labeled the most toxic chemical known to mankind. Its ubiquitous 
presence in the environment as well as questions concerning its 
teratogenic, carcinogenic, and immunotoxic properties and its effect 
on the reproductive system have facilitated federal spending of more 
than one billion dollars—as calculated by A.L. Young of the Office of 
Science and Technology Policy—for research and other dioxin-related 
concerns even before all major studies still in progress have been 
completed.^ Additional funds have been allocated by chemical 
companies, private organizations and government agencies. Incidents 
such as the first documented industrial accident in 1949 at a plant 
owned by the Monsanto Company in Nitro, West Viginia, where 228 people 
were exposed to the compound and another in 1976 when an entire 
community was exposed in Seveso, Italy, have only heightened 
2 
scientific concerns. These are just two of the many (Table I) 
incidents of dioxin exposure to the environment and mankind that have 
attracted the attention of scientists and public health officials 
around the world, not only because of real or presumed danger, but 
also because of the extremely challenging scientific issues present. 
Public outrage has been expressed over incidents in the state of 
Missouri, where roads, trailer parks and recreational arenas were 
covered with an oil contaminated with dioxin. Concern about dioxin and 
its effects upon humans has also become embroiled in a legal dispute. 
1 
Table 1.-Industrial Accidents Associated With The Manufacture of Chlorinated Phenols 
Year 
Manufacturer and/or 





1949 U.S.A. Monsanto/Nitro,West TCP E 228 
Virginia 0 
1952 West Germany Bochringer/Hamburg TCP 0 31 
1953 West Germany BASF/Ludwigshafen TCP E 73 
1956 West Germany Boehringer/Ludwigshafen TCP 2,4,5-T 0 32 
1956 France Rhone-Poulene/Grenoble TCP E 17 
1956 Ü.S.A. Diamond Alkali Corp/New 2,4 5-T 0 29 
Jersey 
1962 Italy ICM/Saronno TCP E 13 
1963 Netherlands Phillips-Duphar/Amsterdam TCP E 106 
1964 USSR Ufa 2,4,5-T 0 128 
1964 U.S.A. Dow Chemical/Midland, TCP 0 61 
Michigan 
1965 Czechoslovakia Spolana TCP 0 80 
1966 France Rhone-Poulene/Grenoble TCP E 21 
1968 United Kingdom Coalite, Chemical Products/ TCP E 85-90 
Bolsober, Derbyshire 
1970 Japan - PCP 2,4,5-T 0 25 
1973 Austria Chemical Works/Linz 2,4 5-T 0 50 
1974 West Germany Bayer/Uerdingen 2,4 5-T 0 5 




A coalition representing Vietnam veterans has settled out of court for 
$180 million from seven chemical corporations: Dow Chemical, Monsanto, 
Diamond Shamrock, Uniroyal, Hercules, T.H. Agriculture and Nitrition, 
and Thompson Chemical, all of which manufactured Agent Orange, a 
herbicide with dioxin as a contaminant. Agent Orange was used as a 
defoliant in the Vietnam War. Vietnam veterans are attributing a number 
3 
of their post-war health problems to exposure to the herbicide. 
The scientific community has long wrestled with this controversial 
issue. In 1984, however, a conference on dioxin at Michigan State 
University concluded that this issue is of less importance than a 
number of other pressing matters and that the nation's limited 
scientific resources should be devoted to issues posing greater 
threats. Many scientists are now beginning to shrug their shoulders, 
convinced that "concern for this material (dioxin) being harmful to 
health or the environment may be misplaced. Although it is toxic to 
certain animals, evidence is lacking that it has any serious long-term 
effect on human beings."'*' In a detailed data analysis for the 
4 
National Academy of Science, Kunstadter compiled records of birth 
defects and perinatal mortality from two hospitals in Saigon that 
treated individuals who may have been exposed to dioxin. Comparing this 
data to U.S. Department of Defense records of geographic and temporal 
distribution of Agent Orange, Kunstadter demonstrated few consistent 
statistically significant results to support the hypothesis that there 
is a positive association between the military use of herbicides in 
Vietnam and the incidence of birth defects in children born to mothers 
5 
exposed during pregnancy. Mocarelli et al in a six-year study of 
3 
the effects of this toxin on a group of children exposed in the 
Seveso, Italy, incident concluded that "the acute phase of 
intoxication by dioxin passed with no appreciable consequences." They 
also proposed that the children continue to be monitored in the future 
to determine if they would incur a higher incidence of tumors. 
The term dioxin describes a family of compounds. Each cogener has 
as its nucleus three rings consisting of two benzene rings connected 
by two oxygen atoms (Figure 1). "Dioxin" is actually a misnomer for 
this compound. The term "dioxin" describes a six-membered ring 
structure with the molecular formula C4H4°2 (Figure 2) . When the 
two oxygen atoms occupy positions opposite to each other in the ring 
as in Figure 2, it is technically referred to as para-dioxin 
(p-dioxin). There are chlorinated and other halogenated dioxins. 
However, the chlorinated dioxins have generated the most interest and 
consist of seventy-five congeners, each with distinctive chemical and 
physical properties and differing from each other by only the number 
and positions of the chlorine atoms on the dibenzo-p-dioxin nucleus. 
They are produced by the substitution of the hydrogen atoms on the 
dioxin nucleus with chlorine atoms. There are 22 tetra substituted 
dioxins and they are referred to as tetrachloro- dibenzo-p-dioxins 
(TCDDs). They may be separated from each other by use of 
high-resolution gas chromatographic/high-resolution mass spectrometric 
analysis (GC/MS) (Figure 3). One of the most toxic compounds known to 
mankind and the cogener studied in the greatest detail is the 
2,3, 7,8-tetrachlorodibenzo-p-dioxin (2,3, 7, 8-TCDD) (Figure 4). 




Figure 1. Dibenzo-p-dioxin nucleus 
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Figure 4. 2,3,7,8—Tetra.ohloircxdiben.zo-p--d±oxiri 
TABLE 2.-Physical Properties of 2,3,7,8-TCDD 
Empiric formula C12H4C14°2 




Molecular weight 322 
Melting point, °C 305 










Water 0.00000002 <0.2ppb) 
8 
across both vertical and horizontal axes, its functional groups are 
not reactive and the compound is chemically very stable. It is 
relatively insoluble in water (0.2 ppb) and sparingly soluble in most 
organic liquids (Table II).^ It is a colorless crystalline solid at 
room temperature and has an absorption maximum at 307 nm in methanol 
and in the presence of a hydrogen donor and ultraviolet light it is 
rapidly degraded into successively less chlorinated dioxins until 
dechlorination is complete (Figure 5) . With each successive loss of 
chlorine, the reaction rate increases, while toxicity of the resulting 
product diminishes. At some point, the dioxin ring system is also 
cleaved to give phenoxyphenols, which in turn are further degraded. 
The expelled chlorine atoms appear as HC1 or combine with the H donor 
7 
m place of the original hydrogen 2,3,7,8-TCDD also has a rather 
-7 
low vapor pressure (1.7 x 10 Torr) and tends not to vaporize in the 
atmosphere and be carried away by the wind. It is practically immobile 
when incorporated into soil and aquatic systems and once incorporated 
2 
has a half-life of one to three years. In humans the median 
g 
half-life appears to be seven years. The strong bond with soil 
makes it very resistant to leaching and to entering groundwater. 
2,3,7,8-TCDD resists thermal degradation; it can be destroyed only at 
temperatures above 800°C. 
2,3,7,8-TCDD is present as an unintentional contaminant during the 
manufacture of 2,4,5-trichlorophenol (TCP). The herbicide Agent Orange 
was a 1:1 mixture of TCP and 2,4-dichlorophenol. A small amount of 
TCDD is also present in the antibacterial agent hexachlorophene, which 





Figure 5. Photochemical degradation route of 2, 3. 7, 8, —TCDD in the 
presence of a hydrogen—donating solvent. 
10 









Ttidilorcphenate 2,3,7, 8-Tetraolilocodibeiizo-p-dloxin 
Figure 7. Production of 2,3,7,8—TCDD from trichlorophenate. 
12 
industrially important chlorobenzenes (Figure 6) and by the classic 
g 
Ullmann dimerization of trichlorophenate (Figure 7). There are no 
published reports indicating the compound is formed biosynthetically 
by living organisms. 
2,3,7,8-TCDD is formed as a by-product during the synthesis of 
2, 4,5-trichlorophenol from 1,2,4,5-tetrachlorobenzene under alkaline 
conditions by the condensation of two molecules of sodium 
9 
trichlorophenate (Figure 8). In the process of making TCP a 
molecule of 1,2,4,5-tetrachlorobenzene is hydrolyzed in the presence 
of caustic soda to form 2,4,5-trichlorophenate. Two molecules of the 
phenate condense to form 2,3,7,8-TCDD. The higher the temperature and 
alkalinity, the greater the amount of TCDD formed. When the mixture 
temperature exceeds 180°C, an exothermic reaction occurs which has 
resulted in a number of industrial accidents. If the temperature and 
pressure are controlled carefully while the reaction is in progress, 
the crude 2,4,5-trichlorophenol contains less than lmg/kg up to a 
maximum of 5mg/kg of 2,3,7,8-TCDD (1-5 ppm). Distillation of the crude 
trichlorophenol reduces the content of 2,3,7,8-TCDD to less than 
O.Olppm (0.01mg/kg) in 2,4,5-TCP. In hexachlorophene, the amount of 
2,3,7,8-TCDD contamination is usually less than O.OOlppm (0.001mg/kg) 
and not higher than 0.005ppm. The maximum amount of 2,3,7,8-TCDD 
allowable in the technical product by the U.S. Pharmacopeia was set at 
0.05ppm (0.05mg/kg). 
2,3,7,8-TCDD may also be formed through various combustion 
processes such as municipal, commercial, and industrial waste 
incinerators.^ It has been shown to be a trace contaminant in the 
13 











Figure 8. Industrial production of trichlorophenol, hexachlorophene, 2,4,5—T and by-product, 2,3,7,8—TCDD. 
It is found in herbicide used to spray power lines and farm crops.11 
12 13 
everything from breast milk to aquatic life to farm 
animals14, and from adipose tissue1^ to now serum.1^ 
Much of the alarm that has surrounded 2,3,7,8-TCDD is due to its 
toxicity in laboratory animals. The acute toxicity of this compound in 
laboratory animals is characterized in most cases by listlessness, 
loss of body weight, delayed lethality (two weeks to two months), and 
by marked interspecies variability in pathology and LD^Q (Table 
III). Acute single dose LD^ values have been found to vary with the 
age, sex and strain of the test animal, with the guinea pig being the 
most sensitive and the hamster the least sensitive of those 
17 
examined. It has proven to be one of the most potent toxic 
18 
chemicals known (Table IV) . In humans a number of health effects 
19 
have been reported due to exposure to 2,3,7,8-TCDD (Table V). 
The chlorinated dibenzo-p-dioxins are lipophilic compounds and the 
adipose tissue initially served as the matrix of choice for 
2,3,7,8,-TCDD analysis due its high lipid content. A number of 
laboratories have successfully completed studies using adipose 
20 21 22 
tissue , , . The method used for sample extraction and 
enrichment of polychlorinated dibenzo-p-dioxins from adipose tissue in 
23 
our laboratory is discussed in detail by Smith, et al . This 
method was developed by Smith and Stalling for the analysis of fish 
15 24 
and subsequently adapted and semiautomated by us ' for the 
extraction and enrichment of human adipose tissue. 
There are, however, several problems associated with the use of 
adipose tissue in accessing 2,3,7,8-TCDD body burden. The most obvious 
15 
Table 3.-Single Dose LDC. Values for 2,3,7,8-TCDD OU 
Species Route LD50 (ug/kg) 
Guinea pig oral 2 
Monkey oral 50 
Rat 
Adult male ip 60 
Weanling male ip 25 
3-MC pretreated 
wealing male ip 44 
Adult female ip 25 
Rabbit oral 115 
Rabbit skin 275 
Mouse 
C57BL/6J ip 132 
DBA/2J ip 620 
B6D2F1J ip 300 
Hamster ip >3000 
Hamster oral 1157 
^interperitoneal 
16 
Table 4.-Toxicities of selected poisons 
Minimum lethal dose 
Substance Animal (moles/kg) 
Botulinum toxin A Mouse 3.3 X 10-17 
Tetanus toxin Mouse 1.0 X IQ'
15 
Diphtheria toxin Mouse 4.2 X lO'12 
2,3,7,8-TCDD Guinea pig 3.1 X 10'9 
Bufotoxin Cat 5.2 X 10-7 
Curare Mouse 7.2 X 10'7 
Strychnine Mouse 1.5 X 10-6 
Muscarine Cat 5.2 X 10-6 
Diisopropylfluoro- 
phosphate Mouse 1.6 X io-5 





Table 5.-Reported health effects due to 2,3,7,8-TCDD in man 
System or finding Symptom 
General Weakness, headache, 
weight loss, 
impotence, insomnia, 





hair loss, nail 
growth, porphyria 










Muscle and joint 
pain, numbness and 
spasm in the limbs, 







Several degrees of 
inflammation with 
burning, discharge, 
edema of eyelid, 
cyst formation of 













problem is that minor invasive surgery is involved. The adipose 
tissue must be surgically removed under local anesthesia. 
Approximately 10g must be excised and a small dimple as well as a 
scar remain. Based on the participation rate in a recent study in the 
20 
state of Missouri, it became obvious that it would be difficult 
to convince a large enough portion of a study group to consent to 
such an invasive procedure. 
There was therefore a need for a more viable alternative to adipose 
tissue for large scale epidemiologic studies. The use of serum seemed 
a reasonable alternative because obtaining a serum sample would be 
far less invasive; a larger study group would be able to participate; 
the cost of obtaining the sample would be less; and there would be 
fewer potential complications in sample procurement. 
The analysis for dioxin in serum is a complex problem. 2,3,7,8-TCDD 
shares extraction properties similar to polychlorinated biphenyls, 
chlorinated dibenzofurans, chlorinated naphthalenes and biogenic 
substances. How does one reduce these potential interferences without 
a simultaneous loss in the 2,3,7,8-TCDD concentration? 
25 
Rappe et al were the first to publish a method for the analysis 
of dioxins in serum of occupationally exposed workers. This procedure 
for cleaning up blood plasma samples was based on partitioning of the 
lipids and their associated dioxins between n-hexane and 
acetonitrile. See appendix A for a detailed description of this 
method. This method, however, could not be used for the extraction of 
the blood plasma volumes needed to detect background levels of 
polychlorinated dibenzo-p-dioxins in the parts-per-quadrillion range. 
19 
An associate of Rappe, Martin Nygren, has developed a more 
sophisticated method for the analysis of the 2,3,7,8-TCDD congener in 
26 
human serum. The extraction is based on the solvent mixture 
chloroform/methanol. See appendix B for a detailed description of this 
method. We have tried this method in our laboratory and have found 
it to be labor intensive, time-consuming, and nearly impossible to 
automate. This method would not be practical for a large-scale study. 
We therefore set out to develop a method that would: 1) allow the 
quantitative measurement of the 2,3,7,8-TCDD isomer, 2) be capable of 
being used for a large-scale study, and 3) closely parallel the 
methodology of the semiautomated adipose tissue method already in use 





There are a number of potential health effects as well as 
27 
expedient laboratory procedures for handling toxic chemicals that 
should be addressed before attempting the analysis of serum for 
2,3,7,8-TCDD or other toxic compounds. The Environmental Protection 
Agency has established guidelines that underscore specific aspects of 
protective equipment, training, personal hygiene, isolation of the 
work area, disposal of waste, laboratory cleanup, laundry, wipe 
28 
testing, problems in inhalation and accidents. Conventional plans 
describing proper procedures in each of these areas as well as a 
monitoring system for conformity should be in place for each 
laboratory. Chemists working with serum should also be aware of 
protective measures and of the risk for contracting the hepatitis B 
and AIDS virus and should adhere to recomendations established by the 
29 
Centers for Disease Control. 
Materials 
15 24 
In addition to the materials already described ' we used 
ethanol (anhydrous reagent, J.T. Baker, Phillipsburg, NJ), ammonium 
sulfate (certified primary standard, Fisher Scientific Co., Fair Lawn, 
NJ), sulfuric acid (Reagent ACS, Fisher Scientific, Fair Lawn, NJ), 
acetone (glass-distilled grade, Burdick & Jackson, Muskegon, MI), 
microsilica (Ludox Colloidal Silica, E.I. DuPont de Nemours Co., 




The following procedures describe the methods this laboratory 
employed in an attempt to analyze human serum for 2,3,7,8-TCDD. 
METHOD 1 : lOmL of quality control (QC) serum was weighed into a round 
bottom (50mL) glass test tube and spiked with 240pg of 
13 
[ C^23”2,3,7,8-TCDD which served as the internal standard. The 
internal standard is maintained at room temperature and is accurately 
measured using a microman precision positive displacement pipette 
(Raninin Instrument Co. Inc., Woburn, MA) with disposable microliter 
pipet tips. The pipet tip is submerged 2-3mm below the surface of the 
standard and operating the pipet for pickup and dispensing back into 
the standard. A repeat operation is done for pickup and dispensing 
onto the side of the bottle containing the serum. lOmL of aqueous 
saturated ammonium sulfate solution is added. The test tube is 
vortexed for two minutes. Hexane (lOmL) is added and the tube is 
vortexed for an additional 5 minutes. The solution is then allowed to 
stand for 10 minutes and if there is no phase separation, a few drops 
of ethanol are added until a seperation is achieved. The top hexane 
layer is removed and the aqueous layer is extracted twice more with 
lOmL portions of hexane as described above. The total extract (30mL) 
is combined, reduced under a stream of nitrogen to 0.5mL, transferred 
to a 1ml vial with three washings of 0.5mL methylene chloride, and 
evaporated to dryness for analysis by GC/MS. 
22 
METHOD 2 : Serum (200g) was placed into a 200mL beaker and spiked with 
13 
240pg of [ C12)“2f3,7,8-TCDD. The beaker was placed into a bath 
of dry ice/acetone until the sample was frozen solid. A kindlier 
(Kimberly Clark Corp., Roswell, GA) was secured over the top of the 
beaker with a rubber band to keep out any debris. This beaker was 
placed in a lyophilizer (Model USM-15, The Virtis Company Inc., 
Gardiner, NY), whose shelves were pre-cooled to -40°C. The vacuum 
was activated once the condenser temperature reaches -50°C. When the 
vacuum gauge registers 100 microns, the fluid temperature which 
controls the amount of heat given off by the shelves, is set to 
100°C. The lyophilizer is allowed to run overnight. Sublimation of 
the sample begins when the vacuum chamber is evacuated and heat is 
applied to the shelves. The rate of sublimation is governed by the 
rate of heat input. The ability of the refrigerated condenser to 
condense and freeze the vapor released from the frozen product will 
determine the required level of vacuum. The sample is completely dry 
when the condenser temperature has reached its maximum low, the shelf 
temperature has risen and remains at the set point, the vacuum 
pressure is at a maximum low, and the appearance of the sample 
indicates dryness. The sample is then placed into a mortar and 50g of 
sodium sulfate are ground into it with the pestle. The dried serum and 
sodium sulfate are then placed onto the manual extraction system 
23 
described by Smith et al and submitted for GC/MS analysis. 
23 
Method 2.: To demonstrate that the 2,3,7,8-TCDD was being removed by 
lyophilization, lOul of 0.3 millicuries of [^H]-2,3,7,8-TCDD (ICN 
Pharmaceutical Inc., Costa Mesa, CA) was spiked into a 20mL counting 
vial and lyophilized overnight. The next morning lOmL of Unogel 
(Becton Dickinson and Co., Orangeburg, NY), a scintillation cocktail, 
was added. The sample was analyzed using the LS-350 Liquid 
Scintillation System (Beckman Instruments, Inc., Fullerton, CA) . 
Following this experiment serum (200g) was placed into a 200mL round 
bottom flask and spiked with 0.3 millicuries of tritium labeled 
3 
[ H]-2,3,7,8-TCDD. A glass extension was placed into the aperture of 
the round bottom flask. This extension was filled with carbon 
dispersed on glass fiber filter paper and acted as a trap for the 
3 
( H]-2,3,7,8-dioxin isomer. The trap was prepared by weighing into a 
beaker 1400g of glass fiber-grade 141 filter paper (American Hospital 
Supply Corp., McGraw Park, IL), 140g of Amoco active carbon-grade 
PX-21 (Amoco Research Corp., Chicago, IL), and 140mL of methylene 
chloride. A tissumizer (Tekmar, Cincinnati, OH) was used to ensure 
that the carbon was evenly dispersed on the glass fibers. The 
carbon/fiber solution was dried and loosely packed into the glass 
extension. The trap was placed into the opening of the round bottom 
flask and the the sample was lyophilized overnight. The following 
morning the carbon/fiber trap was removed, back washed into a 20ml 
counting vial with lOmL of toluene, dried under a gentle stream of 
nitrogen, and lOmL of Unogel was added and analyzed with the 
spectrophotometer. The serum, which had partially dried, was allowed 
to liquefy and was transferred into a five-liter reagent bottle which 
24 
was then processed as in Method 2 (lyophilized for one week). 
METHOD 4: Serum (lOOmL) was spiked with 240pg of 
13 
[ -2,3,7,8-TCDD and extracted by the system illustrated in 
Figure 9. The serum sample was placed into column I. Ethanol (50mL) 
was added to help prevent emulsion. Hexane was pumped into the column 
and passed through to a clean-up column (column II). The solvent then 
passed through a carbon column (column III). The sample was allowed to 
recycle until the extraction of all dioxin was thought to be complete. 
The carbon was then back washed with toluene and processed through 
23 
columns IV and V as described by Smith, et al. 
METHOD 5: 200mL of serum is heated to 37°C with slight stirring. 
Trypsin (lmg trypsin per 50mg protein) and chymotrypsin at (lmg per 
50mg protein) are added. The solution is maintained at 37°C and 
gently stirred for 24 hours. The serum is then extracted by Method 4. 
METHOD 6: Serum (200g) is weighed into a 250mL reagent bottle and 
13 
spiked with the internal standard [ C^l -2, 3,7,8-TCDD and allowed 
to equilibrate at room temperature for 30 min. A stirring bar is added 
and the serum is placed onto a magnetic stirrer at low speed. 0.067mL 
of microsilica is added per each 1.OmL of serum in a drop-by-drop 
fashion. The microsilica should not be added too quickly or it will 
clump at the bottom of the container. The mixture is allowed to stir 
for three hours. The microsilica removes the lipid components of the 
serum while leaving the aqueous portion behind. The microsilica/serum 
25 
COLUMN I 
Figure 9. Diagram of recycling system. 
26 
solution is then transferred to a 200ml centrifuge tube and spun for 
two hours at lOOOrpm. The supernatant is discarded and the pellet is 
resuspended in 50mL of ethanol. The centrifuge tube is then placed 
into a sonicator for one minute. The microsilica pellet is then 
extracted three times with lOOmL portions of hexane by adding the 
lOOmL of hexane, shaking for 10 minutes and centrifuging for five 
minutes. The top hexane layer is removed and saved. After each 
extraction the microsilica pellet in the 50mL of ethanol is sonicated 
for one minute before the next volume of hexane is added. The hexane 
extracts are combined for a total volume of 300mL and then dried to 
50mL under a stream of nitrogen. This 50mL of hexane is then washed 
with 30mL of concentrated sulfuric acid in lOmL increments. The 
hexane is then washed three times with lOmL portions of deionized 
water, which is discarded after each wash. The washed 50mL of hexane 
is then further processed through the automated cleanup procedure 
described previously.^ 
METHOD 7 : Serum (200g) is weighed into a 500mL Teflon bottle (Nagle 
Co., Rochester, NY) and spiked with 240 pg of internal standard 
13 
[ C^l 2,3,7,8-TCDD. The sample is capped tightly and shaken 
vigorously with a wrist action shaker Model 75 (Bunnell Corp., 
Pittsburgh, PA) for 30 minutes. To the sample is added 100ml of 
aqueous saturated ammonium sulfate solution, 100ml of absolute ethanol 
and 100ml of hexane. The flask is then capped tightly and shaken 
vigorously for 30 minutes with the wrist action shaker. The emulsion 
formed after shaking is centrifuged for 10 minutes at 1500 rpm. The 
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top hexane layer is transferred to a 500mL Teflon separator funnel. To 
the bottom aqueous layer is added another lOOmL of hexane, followed by 
vigorous shaking, centrifuging and combining of the two hexane 
extracts. The combined hexane extracts (200 mL) are then washed with 
concentrated sulfuric acid in a 500mL separator funnel with a total of 
200mL of concentrated sulfuric acid in 20mL aliquots. The first three 
extractions are not shaken vigorously to prevent the formation of a 
thick emulsion. The acid-washed hexane is further extracted with a 
total of 75 mL of deionized water in 25mL aliquots. The hexane is then 
transferred to a 250mL Erlenmeyer flask, followed by the addition of 
10g of sodium sulfate and evaporation under a nitrogen stream to 75 
mL. The sample is then loaded onto the first chromatography column for 
part I of a two-part sample cleanup procedure, which is capable of 
15 24 
processing five samples unattended overnight. ’ 
Inatmasatal Analysis 
13 
Samples spiked with [ C^l 2,3,7,8-TCDD were all analysed 
using an analytical instrument system consisting of a VG ZAB-2F high 
resolution mass spectrometer with a VG 11/250J data system and 
Hewlett-Packard 5890 gas chromatograph. The analyses were conducted in 
an isomer-specific mode, with a 60M SP2330 capillary column. The 
injection is spitless with a 30-sec purge. The injector temperature is 
240°C. The initial column temperature of 100°C is held for 2 
minutes, then programmed to 220°C at 25°C/minute and held for 2 
minutes, and then programmed to 250°C at 15°C/minute, and held for 
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14 minutes. The average linear velocity of helium is 23cm/s or about 
2.9 mL/minutes flow rate. The mass spectrometer is operated in the 
high-resolution (static RP = 10000 at 10% valley) selected ion 
recording mode, with perfluorotributylamine used to provide a lock 
mass at m/z 314. Peak top jumping is accomplished by stepping up the 
accelerating voltage after any necessary correction during the scan of 
the lock mass. Ions m/z 320 and 322 provide a measure of the native 
TCDD, and ions m/z 332 and 334 are monitored for the elution of the 
labeled internal standard. Five analytical standards that correspond 
to 1.25-25 ppq of 2,3,7,8-TCDD in a 200g serum sample have been used 
to establish a linear calibration curve.^ The internal standard is 
13 
the [ -2,3,7,8-TCDD at a concentration corresponding to 1.2 
ppt in the original 200g samples. The other TCDD isomers can be 
quantitated by using published response factors relative to 
2,3,7,8-TCDD.^ The best precision in quantification is obtained by 
using chromatographic peak areas and by using the sum of the two ions 
for the native TCDD and two ions for the internal standard. We also 
use the ion m/z 331.9078 of [*3C,]-1,2,3,4-TCDD and m/z 331.9368 
b 
13 
of [ C^l”2,3,7,8-TCDD to demonstrate 10,000 RP for every mass 
spectral analysis. To completely separate these two ions requires > 
11,454 RP and therefore, at 10,000 RP the ratio of the peak on the 
[^C^l-2,3,7,8-TCDD (331.9078) channel due to 
[13C6]-1,2,3,4-TCDD, 
t0 th® peak °n the [13c6]-1,2,3,4-TCDD 
(331.9078) channel can be plotted for each analysis. 
On a regular basis, isomer-specific chromatography is demonstrated 
by analyzing a standard containing the 22-TCDDs. Our serum Quality 
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by analyzing a standard containing the 22-TCDDs. Our serum Quality 
Control (QC) pools L and H contain, among other dioxins and furans, 
the 1,2,3,4-TCDD isomer that can be used to establish isomer 
specificity for 2,3,7,8-TCDD in analytical runs containing a sample 
from these QC pools. The calibration curve is verified by analyzing 
at least three analytical standards during an eight hour shift. 
Instrument resolution at 10,000 RP, tuning and other parameters are 
checked on a regular basis to ensure optimum sensitivity and 
specificity. Criteria for a positive TCDD determination are as 
follows: (1) signal/noise greater than 3/1 for both signals on ions 
320 and 322; (2) signal/noise greater than 10/1 for both signals on 
ions 332 and 334 from the internal standard; (3) observed retention 
+1 scan of each other on ions 320 and 322 and the relative 
13 
retention time (RRT) (to [ “2r 3,7,8-TCDD) must be within 2 
part-per-thousand of the RRT of the analytical standard; (4) the 
ratio of the intensities of the ion 320 to 322 and 332 to 334 is 
within the 95% confidence intervals established for these ratios 
(Table VI). 
Spiked and nonspiked human serum QC material has been prepared 
and characterized. Incorporating these materials in the analytical 
run sets control limits and provides a means for demonstrating that 
the analytical system is in control. Recovery data are calculated 
on the basis of the absolute area counts for m/z 332 +334 in the 
sample vs. the external standards. 
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Percent recovery is expressed as the ratio: 
(A332 + A334)/A332* (unknown) 
% Recovery =  x 100 
*A332 + A334^A332* (standard) 
The area counts for the ions and A334 (unknown) represent the 
13 
amount of [ C^l "2,3,7,8-TCDD recovered after any losses due to 
sample cleanup and high resolution gas chromatography/high resolution 
mass spectrometry. The ion (unknown) is the area counts of the 
13 
[ Cg]-1,2,3,4-TCDD isomer that is in the five microliters of 
toluene used to reconstitute the sample. The (A.^ + A334^A332* 
(standard) is determined by using the standard which was analyzed just 
prior to the start of the analytical run (blank, 3 unknowns, QC). 
The in-vivo 2,3,7,8-TCDD response factor is expressed as the ratio 
of the following ion areas: 
Response factor = 
A?2Q + A3,22 
A332 + A334 
12 
The m/z 320 and 322 ions measure the in-vivo [ C^l -2,3, 7,8-TCDD 
isomer in the sample and the m/z 332 and 334 ions measure the internal 
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13 
standard, ([ C^] 2,3,7,8-TCDD) . A plot of the response factors 
versus the known concentration for each standard establishes a linear 
regression calibration curve for the native TCDD. The concentration 
(x) of an unknown sample (pg) is calculated from the slope (m) and 
intercept (b) of the linear calibration curve: 
v = 2 
J a a 
332 + 334 
Quality Assurance (QA) Program 
Quality Control (PC) Materials.: To adequately demonstrate that the 
analytical system is functioning properly three pools of human serum 
were prepared. Two were spiked with different levels of dioxins and 
furans. The third pool was not spiked. The spiked pools contain the 
following dioxins 
and furans in addition to those already present in human serum: 
2,3,7,8-TCDD; 1,2,3,4-TCDD, 1,2,3,7,8-pentachlorodibenzo-p-dioxin 
(PnCDD); 1,2,4,7,8-PnCDD; 1,2,4, 6,7, 9-hexachlorodibenzo-p-dioxin 
(HxCDD); 1,2,3,6,7,9-HxCDD; 1,2,3,6,7,8-HxCDD; 1,2,3,7,8, 9-HxCDD; 
1,2,3, 4, 7,8-HxCDD; 1,2,3,4,6,7, 9-heptachlorodibenzo-p-dioxin (HpCDD); 
1,2,3, 4, 6,7,8-HpCDD; octachlorodibenzo-p-dioxin (OCDD); 
2,3,7, 8-tetrachlorodibenzofruan (TCDF); octachlorodibenzofuran (OCDF). 
PC Charts: QC charts graphically document the analytical performance 
32 
PROGRAM MOME [5 05EP.ÛC 
la RUNS RS OF 7/17/1985 
Chart 1. Confidence limits established for QC pool I. 
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Table 6.-Statistical Data for the Human Serum QC Pools 
a 
H, pptb I, ppq° L, pptb 
concn of 2,3,7,8-TCDD 6.83 25.8 1.93 
N (sample size,g) 8 (10) 20 (200) 22 (10) 
coeff of variation 9.4 13.0 15.5 
99% control limits, upper 8.48 34.4 2.70 
99% control limits, lower 5.18 17.1 1.16 
95% control limits, upper 8.08 32.3 2.51 
95% control limits, lower 5.57 19.2 1.35 
m/z 320/322 ratio 86.7 79.3 80.4 
N (sample size,g) 8 (10) 20 (200) 22 (10) 
std dev 2.6 9.45 6.28 
coeff of variation 2.9 11.9 7.8 
99% control limits, upper 93.3 103.7 96.6 
99% control limits, lower 80.1 54.9 64.2 
95% control limits, upper 91.7 97.9 92.7 
95% control limits, lower 81.7 60.8 68.1 
m/z 332/334 ratio 77.6 77.1 75.0 
N (sample size, g) 8 (10) 20 (200) 22 (10) 
std dev 6.2 5.12 4.04 
coeff of variation 8.0 6.6 5.4 
99% control limits, upper 93.7 90.3 85.4 
99% control limits, lower 61.6 63.9 64.6 
95% control limits, upper 89.8 87.1 82.9 
95% control limits, lower 65.4 67.0 67.1 
aAll pools analyzed by method 7. 
°These pools spiked with dioxins and furans described in 
text. 
This pool is an unspiked composite pool from 67 
individuals. 
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of the system. Chart 1 shows the QC chart for pool I, which was 
established during the development of this method; statistical data 
for the confidence limits are shown in Table VI. 
Details of the Analytical Run.: The status of the specimens being 
analyzed is unknown to the laboratory analysts. Samples are arranged 
in analytical runs of five (A method blank , 3 unknowns, and a QC 
sample). The MS personnel are also unaware of the nature of the 
extract. To minimize the possibility for carryover or 
cross-contamination of samples and analytical standards, analysts use 
separate syringes for samples and for each analytical standard. The 
syringes used for the unknown samples are discarded after one use. 
Between injections of a standard or sample, the syringe is inserted 
through a Teflon-coated septum into a 15-mL vial containing 12mL of 
toluene, and the barrel is filled and emptied 10 times. This process 
is repeated twice more with different 15-mL vials containing toluene. 
A final wash of the syringe is done by filling and emptying the barrel 
10 times with a fourth toluene wash solution. These wash solutions are 
discarded at the end of each working day. The five microliters for 
reconstituting samples is taken from a stock solution containing 
13 
[ Cg]-1,2,3,4-TCDD in toluene. The detailed step-by-step 
procedure leading to an analytical result, the accompanying 
documentation, and the criteria for identifying and reporting TCDD 
results have been presented previously."^ A brief outline follows: 
(1) Calibrate and tune the mass spectrometer to 10,000 resolving power 
(RP) according to the instrumental protocol; (2) Inject a standard 
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that corresponds to lOOfg of 2,3,7,8-TCDD and begin a clearing run by 
programming the SP 2330, 60M capillary column, after an initial 2 
minutes at 100°C, to 180°C at 20°C/minute, followed by an 
increase to 220°C at 3°C/minute. The column temperature is then 
held at 220°C for an additional 40 minutes for a total run time of 
60 minutes; (3) Verify that the signal-to-noise (S/N) ratio for the 
[^c^]-2,3,7,8-TCDD (m/z 331.9368) is greater than 10 to 1; (4) 
Verify that the S/N ratio for the unlabled 2,3,7,8-TCDD (m/z 319.8964) 
is greater than 3 to 1; (5) Calculate the ratio of the peak areas for 
[13C12]-2,3,7,8-TCDD and [
13Cg]-1,2,3,4-TCDD in the m/z 
331.9078 channel, and compare this ratio to the previously determined 
99% confidence interval to verify that the resolution is greater than 
10,000; (6) Calculate the ratio of the area counts for m/z 331.9368 
(internal standard) and m/z 331.9078 (external standard) to be used to 
calculate the percent recovery for the samples; (7) Verify the isomer 
13 
specificity of the capillary column using the [ C^2]*2,3,7,8-TCDD 
13 
and [ Cg]-1,2,3,4,TCDD ion chromatogram; (8) Inject 
twomicroliters of a randomly selected analytical standard and 
calculate the concentration for this standard using published'*'3 
linear regression parameters. If the concentration is within the 95% 
confidence limits for this standard, the first sample of the 
analytical run may be analyzed; (9) Reconstitute (with five 
13 
mxcroliters of toluene containing [ Cg]1,2,3,4-TCDD) and analyze 
the first sample (this will be a method blank carried through the 
entire sample cleanup procedure). Samples are reconstituted at least 
30 minutes before analysis to ensure that the samples are completely 
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dissolved. (10) Analyze the second, third, fourth and fifth samples. (11) 
Inject two microliters of another randomly selected analytical standard 
and calculate the concentration for this standard using the published1^ 
linear regression parameters. If the concentration is within the 95% 
confidence limits for this standard, the first sample of the next 
analytical run may be analyzed. (12) The results for each analytical run 
will contain at a minimum the following documentation: (a) the 
concentration of 2,3,7,8-TCDD reported in parts per trillion (picograms 
of 2,3,7,8-TCDD per gram of serum lipid) and also the concentration of 
any other TCDD detected, based on the response factors for those 
isomers;(b) the original wet weight of the sample analyzed; (c) the 
percent lipid content of the sample; (d) if no TCDDs are quantifiable, 
then the appropriate result will be reported as nondetected or not 
quantified; (e) the response ratios of m/z 320/322 
and 332/334 for each detected TCDD; (f) the results of all blanks, and 
split duplicates; (g) the current updated QC charts applicable to the 
analytical run; (h) the chromatograms for all samples and standards, 
including the raw peak response data; (i) the current calibration curve 
used for quantification of 2,3,7,8-TCDD; (j) the current response factors 
used to semiquantitate TCDDs; and (k) the mass chromatograms for the 
determination of the degree of isomer specificity. 
Validation of 2.3.7,8 TCDD Analytical Standards 
In a previous analysis of a series of 2,3,7,8-TCDD standards received 
from various laboratories and chemical suppliers, we found that the 
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stocks varied from -65% to +35% of the stated concentration^. 
Because of these findings, we validated our stock solution against 
2.3.7.8- TCDD that we had synthesized and characterized in our 
laboratory. At the time of the previous report, the National Bureau of 
Standards (NBS) had plans to issue a Certified Reference Material for 
2.3.7.8- TCDD, which is now available. Therefore, we have validated our 
stock standard solution that we used for our quantitative measurements 
against CDC synthetic material, EPA and NBS analytical standards. The 
16 
result were published by Patterson et al . The agreement among 
these standards is very good and well within the stated uncertainty. 
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RESULTS ^VISJD ID X SCUS S XON 
Mçtfrpd 1 
Table VII lists the data obtained from the analysis of eight lOmL 
samples from human serum QC pools. A typical chromatogram of a sample 
analyzed by GC/MS from Method 1 is in Figure 10. 







1 0.7 1.7 
2 0.6 5.9 
3 10 3.7 
4 11 4.1 
5 22 8.5 
6 11 4.3 
7 12 4.6 
8 10 3.8 
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The data obtained with Method 1 demonstrate that it is not a viable 
method for the analysis of 2,3,7,8-TCDD in human serum. The recovery 
13 
of the [ "2,3,7,8-TCDD isomer was too low (0.6-22%) to 
provide the required sensitivity for analysis of normal human serum 
(Figure 10). This method was not successful in the removal of 
interferences from the sample and caused the mass spectrometer to go 
down on a number of occasions. If this method were scaled up it would 
have to be altered so that the number of interferences in the samples 
would be reduced. 
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Figure 10. Chromatogram of native 2,3,7,8-TCDD and internal standard 
for Method 1. 
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Meth<?4 2 
Only one sample was analyzed by lyophilization (Figure 11). The 
percent recovery for this sample was 0.4%. 
One of the problems with using silica based absorbents, which we 
hoped to use in the analysis of human serum for 2,3,7,8-TCDD, is that 
if water gets onto the columns they become clogged. Method 2 was 
thought to be a way by which this aqueous liquid portion of the serum 
sample could be removed resulting in a solid dry matrix. Unfortunately 
the level of vacuum created during the process appears to facilitate 
the volitalization of the 2,3,7,8-TCDD out of the sample. The 
chromatogram in Figure 12 illustrates that none of the internal 
standard spiked into the sample prior to lyophilization was recovered. 
There is also the possibility that the dioxin becomes inextricably 
bound to the lipoproteins in the serum during the lyophilization 
process. 
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Figure 11. Chromatogram of native 2,3,7,8-TCDD and internal 









For the two vials spiked with the [ H]-2,3,7,8-TCDD the percent 
recovery was 29% and 23%. Only one serum sample was analyzed by this 
method (Table VIII). A one hundred percent recovery standard was 
3 
established by spiking a counting vial with [ H]-2,3,7,8-TCDD (ten 
microliters of 0.3 millicuries). 
3 
Table 8.-Recovery of [ H]-2,3,7,8-TCDD in Spiked Samples 
Recovery of [3H]-2,3,7,8-TCDD 
[3H]-2,3,7,8-TCDD 1st wash 2nd wash 
added to sample CPM (%) CPM (%) 
CPMa 
55,927.7 36.6 (0.07) 72.0 (0.1) 
CPM is counts per minute 
Due to the low recovery of the standard in the counting vials in the 
first part of this experiment we concluded that the effect of the 
lyophilizer on the sample was removal of the 2,3,7,8-TCDD. In an attempt 
to take advantage of this effect of the lyophilization process to remove 
2,3,7,8-TCDD from the serum, we placed a carbon trap above the sample. 
Theoretically, if the dioxin is being removed it might become imbedded 
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in the carbon trap and all that would be needed to extract the 
2,3,7,8-TCDD from the serum would be to lyophilize the sample, back 
wash the trap with toluene, dry the sample down and submit it for 
GC/MS analysis. The level of vacuum in the lyophilizer is determined 
by the ability of the refrigerated condenser to condense and freeze 
the vapor released from the frozen product. The rate of vapor release 
is governed by the rate of heat input form the lyophilizer's shelves. 
If too much heat is added, the sample will melt and sublimation will 
not take place. If too little heat is added the process of sublimation 
will take a long time to be complete depending on sample size. If the 
vapors are not allowed to escape, as in Method 3, sublimation will 
take a very long time. Indeed the sample never completed sublimation 
even after one week of lyophilization. 
45 
The data from attempts to analyze serum by the recycling method are 
presented in Table IX. 
Table 9.-Analysis of Human Serum by Method 4 
Sample Percent Concentration (pg) of 
number recovery (%) 2,3,7,8-TCDD (ppq) 
1 26 12.5 
2 12 4.9 
3a 52 27.6 
4 NDb NDb 
aBovine serum 
bSee Figure 12 for the chromatogram from this analysis. 
Only the 1,2,3,4-TCDD added prior to mass spectral analysis 
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internal standard for Method 4. 
47 
Method 5 
Figure 13 is an ion chromatogram for the enzyme digestion of serum 
followed by analysis by Method 4. The percent recovery for this sample 
was 5% and the amount of 2,3,7,8-TCDD recovered was 12.5pg. A small 
13 
t C^l-2,3,7,8-TCDD peak (see arrow on Figure 13) was detected 
and in order to quantify this result the graph was expanded (Figure 
14) . 
The major problem with Methods 4 and 5 (recycling of the extracting 
solvent) was an emulsion. The addition of ethanol alleviated the 
problem for a short time but it would return during the two hours that 
the recycling process was carried out. As a result of this emulsion, 
the recovery of the internal standard was dramatically decreased. The 
emulsion would spread from column I onto column II (Figure 9) and the 
system would be contaminated. Even with the addition of the proteases, 
trypsin and chymotrypsin, the emulsion would reappear. Figure 12 
13 
depicts only the recovery of the [ Cg]-1,2,3,4-TCDD isomer. There 
13 
was no detectable amount of the [ C^l “2/ 3, 7, 8-TCDD recovered. 
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Figure 13. Chromatogram of native 2,3,7,8-TCDD and internal standard 
for Method 5. 
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Figure 14. Expanded chromatogram for native 2,3,7,8-TCDD for Method 5. 
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Method $ 
A summary of the results from the microsilica treatment of unspiked 
human serum pools (200g samples) is given in Table X. 
Table 10.-Concentration of2,3,7,8-TCDD in Quality Control Pools 
Human serum 
pool 






c 3 21.7 4.1 19 78 
d 2 18.8 0.3 1 56 
g 4 30.1 9.8 33 59 
h 2 38.2 8.7 3 66 
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Method six proved to be a justifiable means for the analysis of the 
2,3,7,8-TCDD in serum. There was more than adequate recovery of the 
internal standard:the mean recovery for this method was 65%. The 
difficulty with this procedure was the amount of time needed to clean 
up the sample. To process five samples would take four days and the 
method is very labor intensive. 
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The statistical data for the target versus the found concentrations 
for "spiked" serum is presented in Table XI 
Table 11.-Recoveries of 2,3,7,8-TCDD in "Spiked " Human Serum Analyzed 
by Method 7 
Aliquot 
added Target3 
Found (200a samples) 
1 2 3 4 mean obsd bias,% 
A 49.8+5.1 42.0 39.0 32.0 64.2 44.3+12.0 -11.0 
B 72.2+3.5 78.5b 65.5 74.0 80.9 74.7+5.9 +3.5 
C 95.5+6.9 75.5 73.5 90.0 112.5 87.9+15.6 -8.0 
aThe target value was calculated by adding calibrated aliquots to 
the pool I (x=25.8 +3.4 ppq). Aliquot A = 24.0 + 3.8 ppq (N = 5); 
B= 46.4 +.06 ppq (N = 3); C = 69.7 + 6.0 ppq (N = 5). 
^Undetermined amount of sample spilled. The internal standard ion 
counts were low. 
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Method 7 
Serum samples weighing 200-g, 50-g and 10-g were all spiked with 
13 
[ 3,7,8-TCDD and processed by Method 7. The percent 
13 
recoveries for the [ C^l “2,3,7,8-TCDD internal standard are in 
Table XII. 








In Method 7, human samples (200g, 50g, 10g) were spiked with 240 pg 
13 
of [ ”2,3,7,8-TCDD and gave an average recovery of 69%, 54%, 
and 86% respectively (Table XII). Concern that the 2,3,7,8-TCDD isomer 
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was binding to the active sites on the glass in which the serum was 
spiked prompted a switch to teflon. All 200g serum samples examined 
have produced sufficiently strong signals (signal-to-noise ratio > 
3/1) to permit quantification. With regular routine maintenance, a 
limit of quantification of 5 ppq for a 200g sample may be readily 
achieved for routine samples from epidemiological studies. We have 
15 
previously defined our criteria for reporting samples as 
quantifiable, nonquantifiable and nondetectable. The accuracy of 
Method 7 is demonstrated in part by the spiked recovery experiments 
(Table VI). In these tests, three different calibrated aliquots of 
2,3,7,8-TCDD were spiked into separate 200g samples of pool I. This 
experiment was performed twice by two different analysts. The 
concentrations obtained using Method 7 are in good agreement with the 
expected values. Another measure of system performance is the 
precision associated with characterizing QC materials (see Table VI). 
For spiked 10g serum samples at the 1.9 ppt level, a coefficient of 
variation (CV) of 15% was observed. For 200g unspiked samples at the 
25.8 ppq level, a CV of 13% was observed. 
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CONCLUSION 
An analysis of all the data in this study indicates that only two 
methods provide an adequate means of accessing exposure to 
2,3,7,8-TCDD (chart 1). However, factors other than percent recovery 
must also be taken into consideration when deciding which method is 
more feasible. These factors are: 1) the time needed for completing 
the analysis; 2) the amount of labor involved in processing the 
sample; and 3) the size of the study to be undertaken. Based on these 
criteria Method 7 is the method of choice. 
The success of this method has been demonstrated in a number of 
31 
studies. Patterson et al have demonstrated that the mean 
partitioning ratio between adipose and serum 2,3,7,8-TCDD is 1.09. 
This value is obtained after adjusting for the total lipid content of 
the sample. On the same lipid weight bases, the adipose tissue and 
31 
serum levels of 2,3,7,8-TCDD were highly correlated(r = 0.98). 
g 
Pirkle et al have determined the median half-life of 2,3,7,8-TCDD 
to be 7.1 years in humans. The first large scale study to evaluate 
2,3,7,8-TCDD levels in US Amy Vietnam veterans was conducted by 
Method 7 to determine if military records can be used to identify 
32 
veterans exposed to Agent Orange. The Centers for Disease Control 
compared current 2,3,7,8-TCDD levels of Vietnam veterans with exposure 
estimates based on military records and with TCDD levels of veterans 
not serving in Vietnam. The study concluded that levels of 
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Chart 2. Percent recoveries for various methods. 
i 
exposure to Agent Orange, as estimated from military records or 
self-reported exposure. It is hoped that with the success of Method 7 
epidemiologic studies, which require estimates of the body burden of 
2,3,7,8-TCDD, may be completed so that the perceived or real health 
consequences brought on by exposure to this toxin may be elucidated. 
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Dr.Rappe's serum extraction procedure 
N-Hexane (lOmL) was added to 10 mL of blood plasma. Each sample was 
spiked with 0.1 ng of [^C^]~2,3,7,8-TCDD or 
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[ Cl4]-2,3,7,8-TCDF, extracted with three 20mL portions of 
acetonitrile saturated with n-hexane and centrifuged. The combined 
acetonitrile extracts were treated with 10 mL of 1% aqueous sodium 
sulfate and extracted three times with 20 mL of n-hexane. The 
combined n-hexane layers were dried with sodium sulfate, concentrated 
to 2 mL, and then added to a lg alumina column. The column was eluted 
first with 10 mL of 2% methylene chloride in n-hexane and thereafter 
with 10 mL of 50% methylene chloride in n-hexane. The first elute was 
discarded, and the second was concentrated and analyzed by GC/MS. 
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M£ENDix_B 
Dr. Nygren's serum extraction procedure 
To a separatory funnel containing 200mL of blood plasma, is added 
500mL of methanol followed by gentle shaking. Chloroform (250mL) is 
added with gentle shaking followed by an additional 250mL of 
chloroform and gentle shaken. This is allowed to sit overnight in 
order to separate. After separation, 250mL of water is added and the 
bottom layer of chloroform is removed and saved. The methanol/water 
layer is again washed with 400mL of water and the bottom chloroform 
layer is removed and combined with the first chloroform layer. Water 
(750mL) is then added to the chloroform and the mixture allowed to 
separate overnight. The chloroform is removed and passed through a 
separatory funnel plugged with glass wool and filled one-third full 
with sodium sulfate. It is collected in a tared 500mL round-bottom 
flask, concentrated to 2mL and placed into a desiccator overnight. The 
flask is then heated for two hours at 130°C to ensure complete 
dryness of the extracted lipids, removed and allowed to equilibrate at 
room temperature for two hours. The flask is then reweighed 
gravimetrically to determine the fat content of the original 200g 
plasma sample. The plasma sample extract is reconstituted in 15mL of 
hexane and the internal carbon-13 labeled standards are added and 
allowed to equlibrate for 30 minutes. The sample is then placed onto a 
column prepacked with: 1) 25g of 44% H2S04-silica, 2) 20g of 22% 
H2^°4' ^ of silica gel, and 4) 10g of anhydrous sodium 
sulfate. The sample container is rinsed with three washings of 5mL of 
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150mL of hexane is then added to the column. All fractions are 
collected in a round bottom flask that contains 50ul of dodecane, a 
keeper solution to prevent losses of the dioxins upon evaporation of 
the sample. The sample is evaporated to lmL and is transferred to a 
carbon column packed with a mixture of 0.5g Carbopack C and Celite 545 
(18%/82%) which has been activated at 130°C for six hours, had an 
elution check performed on it and stored in a desiccator. The carbon 
column is prewashed with 20mL of toluene, 6mL of dichloromethane, and 
15mL of n-hexane. The sample is transferred to the carbon column with 
3 x 1 mL portions of n-hexane. The isomers of interest are eluted with 
40mL of toluene. 3ul of dodecane is added and the sample is rotovaped 
until almost dry. The sample is then transferred to a glass vial with 
3 x lmL washings of methylene chloride and allowed to evaporate until 
dry. The sample is reconstituted with 5ul of toluene and 2ul are used 
for mass spectral analysis. 
64 
APPENDIX C 
Centers for Disease Control's serum extraction procedure 
MM AMl Cham 1MT. St. 2000-ZOOS 
High-Resolution Gas Chromatographic/High-Resolution Mass 
Specirometric Analysis of Human Serum, on a Whore-Weight 
and Lipid Basis for 2,3,7,8-Tetrachlorodibenzo-p-dioxin 
•• r* • 
Donald G. Patterson. Jr.* Larry Hampton. Chester H. Lapaza. Jr. William T. BaUar. Vaughn Groan. 
Laois Alexander, and Larry L. Needham 
Division of Environvuntal Health Laboratory Sciences, Center for Environmental Heaith, Centers for Disease Control. 
Public Heaith Service, C.S. Department of Health and Human Services, Atlanta, Georgia 30333 
Wa describe an anhytlcai method to measure 2.3.7.8-tetrs- 
cMoroalbenzo-p-dlagon (TC3D) and other TC30 Isomers in 
human serum; the method uses a highly specific eteanuo 
procedure and high resolution gas chromatograony/Ngh-res- 
ahadon mass spectrometry. The 2.2.7.3-TC30 Is quamlHed 
by the Isotope dfiutlmi technique with ('°Cnj-2A7.S-TC30 as 
the internal standard. Other TC30 Isomers are estfenatad by 
using published ralettes response factors. The 1.25 part- 
per-guadrlBlon (ppq) limit ot detection for 200-g samples is 
more than adequate for determining 2.3.7,S-TCOO concon- 
batlona in human serum specimens. The method Is modified 
for analyzing 50-g aid 10-g serum samples. Analytical ac¬ 
curacy Is demonstrated by the results obtained In analyzing 
apdeed samples. The method Is shown to be unaffected by 
a number of potandatfy Interfering compounds. A series of 
quality control mat anal Is ised to verify system pedotmanca. 
For 20C-g samples containing 2S.8 ppq of native 2,3,7,8- 
TC30, a coetflcient of variation (CV) of 1331% Is observed 
(n ■ 20). For 18-g samples from a poof fortified with 
2.3,7,8-TCOO (1.9 parts per btBon, n “ 22), a CV of 15.5% 
Is observed. 
primary disarivantage or adipose tissue is that the sample muse 
be obtained surgically. Therefore, a biological specimen, such 
as blood or its components, that can be obtained with a less 
invasive procedure than adipose and that is available from 
all participants, is highly desirable. 
Other lipophilic xenobiotics. such as the chlorinated hy¬ 
drocarbon peedcidas and polychlorinated biphenyls, have been 
determined in both human adipose tissue and serum for years. 
Because the fat content of serum is much lass than that in 
odipoaa tissue, these compounds are in higher concentrations 
in the adipose r.ssua. Consequently, a large volume of serum 
is normally uaed whan those compounds are determined in 
humans. Because 2J.73-TCI5D Is present at the picogram- 
per-gram or pam-per-trillion (pptr) level in adipose tissue, 
any method for determining it in whole blood, plasma, or 
would have to be particularly sensitive as wall as se¬ 
lective. These criteria require methods basad on-gas chro¬ 
matography/mass spectrometry (16). We report here a 
high-resolution gas chromatographic/high-resolution mass 
specirometric method for determining 2A73-TCDD in human 
this method is an adaptation of our method for de¬ 
termining this zenobiodc in human adipose tissue (17,18). 
Intense public health intarest continues to focus on the 
polychlorinated dibenzo-p-diozins and related compounds. 
Humans are exposed to many of these compounds from such 
sources as znunidpri incinerators (1) and automobile exhausts 
(2); other sources, such as the manufacture and usa of com¬ 
pounds for which LU-trichlorophenol is a synthetic inter¬ 
mediate. give rise primarily to 23.7.3-tetrachiorodibenzo-p- 
dsoxin (2J.73-TCDD). The 2J.73-TCDD congener, one of 
22 tetra isomers, reportedly is the moat toxic of these com¬ 
pounds. Studies have documented ha toxicological properties, 
such as acuta oral LD„ (J), teratogenicity (4), carcinogenicity 
(5), and fetotonaty (6) in selected animal spades. However, 
human toxicity undated with exposure to 2J.73-TCDD has 
not been u well documented. Findings of a recent study of 
the residents of a mobile home park in Missouri suggested 
that long-term exposure to 22J.7.S-TCDD is associated with 
depressed call-mediated immunity, although the effects did 
not result in an excess of diniral illness (7). However, in this 
study of health effects and in another (8), exposure was derived 
bom seif-reported histones and not bom body burden mea¬ 
surements. Such measurements are needed in these health- 
ratated studies. 
Polychlorinated dibenzo-p-diozins are lipophilic and thus 
an found in body stores that are high in lipid content. Body 
burden measurements for L3.7.3-TCDD in htim.ne have been 
determined in blood plasma 19), in human milk ( 10.11). and 
m adipose tissue 112-15). The primary disadvantage of the 
breast mille matrix in health-related studies is that the cohort 
■ restricted to fannies within a limited age range. The 
EXPERIMENTAL SECTION 
Safety. Chemina undertaking this' work with 2J.7.3-TCDD 
and other such toxic compounds must understand the potential 
heaith effects of such compounds (19) and prudent-laboratory 
practices for handling toxic chemicals (20). Specific precautions 
have been described (21,22). More recent Environmental Pro- 
taction Agency (EPA) draft methods have emphasized specific 
mpects of protective equipment, training, personal hygiene. 
Isolation of the work area, disposal of waste, laboratory rieamtn, 
laundry, wipe testing, problems in inhalation, and accidents. We 
have described safety precautions in the operation of our Chemical 
Toxicant Laboratory (23), and other laboratories have also de¬ 
scribed their procedures (241. 
Materials. In addition to the materials already described (17. 
18). we used ethanol (anhydrous reagent. J. T. Baker. Phillipsourg. 
NJ), ammonium sulfata (certified primary standard. Fisher 
Srieerifir Co, Fair Lawn. NJ), and sulfuric acid (Reagent ACS. 
Fisher Scientific. Fair Lawn. NJ). 
Sample Preparation. Two hundred grams of serum is 
weighed into a 500-mL Teflon bottle (Neige Co, Rochester. NY). 
An internal standard solution Consistinx of 240 PC of uC-lobotod 
2J.7.8-TCDD is added to the sample. The standard (maintained 
at room temperature) is accurately menirvri by using an electronic 
digital piper (Ramin Instrument Co. Inc. Woburn. MA) wuh 
djfponolemicraiitarpipettipe. The dhpneehle pipet tip is primed 
by dipping the dp 2-3 mm beiow the surface of the standard sod 
operating the pipet for pickup and dispensing bacic into the 
standard. A repeat operadon is dona for pickup and dispensing 
onto the side of the bottle containing the 200 g of serum. The 
sample is capped tightly sue waxen vigorously with e tvrtst action 
■h.ifar Modal 73 (Bunnell Corp.. Pittsburgh. PA) for 20 ma To 
the sample is then added 100 mL of aqueous saturated ammonium 
sulfata solution (50 mL ma 10- to jOgsompioi. 100 mL of ahoohno 
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Table L KniiMtiii CooentnuioB (Parts per Trillion in m lO-c Sample) and Linear Regression Parameter Estimates from 
Mass Spectrometry Calibration 
95% control limits calibrator obsd mean 
»#. , 
... , COMf Of 
lower upper concn bias, % std dev variation; % 
0.0139 0.0346 0.025 0.0243 -3 0.0053 22 
0.0384 0.0595 0.050 0.0490 -2 0.0053 11 
0.0793 . 0.1012 0.100 0.0900 -10 * * 0.0054 6 
0.2433 0.2935 0.250 0-687 7 0.0127 5 
0.4876 0.5148 0.500 0.4912 -2 0.0121 2 
intercept slope coeff of déterminations 
0.000816705 0.0241131 0.9941 
ethanol (50 mL to a 10» to 50-g sample), and 100 niL of hexane 
(50 mL to a 10- to 50*9 sample). The flask is then capped tightly 
and shaken vigorously for 30 min with the wrist action shaker. 
The emulsion formed after shaking is centrifuged for 10 min at 
1500 rpm. The top hexane layer is transferred to a 500-mL Teflon 
separatory rimneL To the bottom aqueous layer is added another 
100 mL of hexane, followed by vigorous shaking, centrifuging, and 
combining of the two hexane extracts. The combined hexane 
extracts (200 mL) are then extracted with concentrated sulfuric 
acid in a 500-mL separatory funnel and a total of 200-mL of 
concentrated sulfuric add (70 mL for 10- to 50-g samples) in 20-mL 
aliquots. The first three extractions are not shaken vigorously 
to prevent the formation of an emulsion. The add-washed hexane 
d then extracted with a total of 75 mL of deionized water in 25-mL 
aliquots. The hexane is then transferred to a 250-mL Erienmeyer 
flask, followed by the addition of 10 g of sodium sulfate and 
evaporation under a nitrogen stream to ~75 mL. The sample 
is then loaded onto the first chromatography column for part I 
of a two-part sample cleanup procedure (17.18). which is capable 
of processing five samples unattended overnight. 
The sample from part I in toluene is then subjected to rotary 
evaporation at 55 °C under —0.1-0.2 atm vacuum after 50 ui of 
dodecane (99%. Aldrich Chemical Co.. Inc^ Milwaukee. WT) is 
added. The toluene solution is carefully taken to about 1 mL and 
then blown to dryness under a gentle stream of nitrogen. After 
the sample is reconstituted in hexane, it is ready for part H of 
the procedure (27). Before evaporation of the final extract to 
dryness. 1 uL of dodecane is added to the conical sample viaL 
This sample extract is reconstituted to 5 uL with toluene con¬ 
taining (l3C,J-1.2.3,4-TCDD as an external standard just before 
analysis by high-resoiurion gas chromatography/ high-resolution 
mess spectrometry (27). 
Instrument Analysis. Our analytical instrument system 
consists of a VG ZAB-2F high-resoiurion mass spectrometer with 
a VG 11/250J data system and a Hewlett-Packard 5890 gas 
chromatograph. Our analyses are conducted in an isomer-specific 
mode, with a 60 M SP2330 capillary column. The injection is 
spiitless with a 30-s purge-. The injector temperature is 240 *C. 
The initial column temperature of 100 °C is held for 2 min, then 
programmed to 220 *C at 25 °C/min and held for 2 min, and then 
programmed to 250 *C at 15 °C/min. and held for 14 min. The 
average linear velocity of helium is 23 cm/s or about 2£ mL/min 
flow rate. 'Hie mass spectrometer is operated in the high-reso¬ 
lution (static RP » 10000 at 10% valley) selected ion recording 
mode, with perfluorotnbutylamine used to provide a lock mam 
at m/z 314. Peak top jumping is accomplished by stepping the 
accelerating voltage after any necessary correction during the scan 
of the lock mass. Ions mjz 320 and 322 provide a measure of the 
native TCDO, and ions m/z 332 and 334 are monitored for the 
eiurion of the labeled internal standard. Five analytical standards 
that correspond to L25-25 ppq of 2J.7.3-TCDD in a 200-g serum 
sample have been used to establish a linear calibration curve. The 
data for the standard curve are tabulated in Table L The internal 
standard, is the (uC|*l-2Ul,7,S-TCDD at a concentration corre¬ 
sponding to 1.2 pptr m the original 200-g samples. The other 
TCDO isomers can be quantitated by using our published (25) 
response factors relative to 2J.7.3-TCDD. The best precision in 
quantitation is obtained by using chromatographic peak areas 
and by using the sum of the two ions for the native TCDD and 
two ions for the internal standard. 
MASS RETENTION TIMS HEIGHT AREA 
319 90 0 HRS 23 MINS 53 SECS 29.9438 188.3833 
321.89 0 HRS 23 MINS S7 SECS 32.4174 217.9545 
331 94 0 HRS 23 MINS 58 SECS 583.6873 3873.7650 
333.93 0 HRS 23 MINS 58 SECS 848.0622 5352.4980 
Figure 1. Mass chromatograms from a 10-g sample of pool L (1.6 
pptr) showing separation Oetween 2.3.7,8- and 1,2.3.4-TCDD. 
On a regular basis, isomer-specific chromatography is dem¬ 
onstrated by analyzing a standard containing the 22-TCDDs. Our 
serum Quality Control (QQ pools L and H contain, among other 
dioxins and furans, the 12L3.4-TCDD isomer that can be used 
to establish isomer specificity for 223,7,3-TCDD in analytical runs 
containing a sample from these QC pools (see Figure l). The 
calibration curve is verified by analyzing an analytical standard 
during an d-h shirt Instrument resolution at 10000 RP. tuning, 
and other parameters are checked on a regular basis to ensure 
optimum sensitivity and specificity. Criteria for a positive TCDD 
determination are as follows; (1) signal/noise greater than 3/1 
for both signals on ions 320 and 322: (2) signal/noise greater than 
10/1 for both signals on ions 332 and 334 from the internai 
standard; (3) observed retention rimes within si scan of each ocher 
on ions 320 and 322 and the relative retention time (RRT) (to 
(“C,J-2UJ,7,8-TCDD) must be within 2 part-per-thousand of the 
RRT of the analytical standard: (4) the ratio of the intensities 
of the ion 320 to 322 and 332 to 334 is within the 95% confidence 
intervals established for these ratios (see Table ID. 
Spiked and nonspiked human serum QC material has been 
prepared and characterized. Incorporating these materials in the 
analytical run sets control limits and provides a means for dem¬ 
onstrating that the analytical system is in control. Recovery data 
are calculated on the basis of the absolute area counts tor m/ z 
332 4- 334 in the sample vs. the external standards. 
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Tabla IL Statistical Data Ur the Homan Strum QC Pools 
• H, pptr* Lppq* Upptr* 
cooca of 2A7.3-TCDD &S3 253 1.93 
N (sample sia. g) 8(10) 20 (200) 22(10) 
ltd dev l«r) 0.64 3.4 030 
coetf of venation 9.4 1X0 1X5. 
99% control lirais, upper 8.48 - 34.4 X70 
99% control limits, lower 5.13 17.1 L16 
95% control limits, upper 8.08 323 231 
95% control limits. lower 5.57 19.2 135 
mfz 320/322 ratio 86.7 793 80.4 
N (sample size, g) 8(10) 20 (200) 22(10) 
std dev (*) 2.6 9.45 638 
coetf of variation 2J9 113 7.8 
99% control limits, upper 93.3 10X7 96.6 
99% control limits, lower 80.1 54.9 642 
95% control limits, upper 91.7 97.9 9X7 
95% control limits, lower 8L7 60.8 6X1 
mix 332/334 ratio 77.6 77.1 75.0 
N (sample size, gj 8(10) 20 (200) 22(10) 
std dev (*> 6.2 5.12 4.04 
coetf of variation 8.0 <5.6 . 5.4 
99% control limits, upper 93.7 903 85.4 
99% control limits, lower 61.6 63.9 64.6 
95% control limits, upper 89.8 87.1 8X9 
95% control limits, lower ■ 65.4 67.0 «7.1 
•Theta pools spiked with dioxins and tarant described in text. 
•This pool unapiked composite serum from 67 individuals. 
Serum Total Lipids. Cholesterol esters, triglycerides, and 
high-density Lipoprotein cholesterol (HDD an determined in 
duplicate by standard mechods (261. Total phospholipids an 
determined in duplicate by a modification (27) of the Folch 
procedure (23). Free cholesterol is determined in duplicate by 
an enzymatic method (29). The summation method (30) estimates 
total lipids in serum. Tha agreement is excellent between this 
summation value and tha corresponding estimate obtained 
through extraction and gravimetric analysis (30). 
QUALITY ASSURANCE (QA) PROGRAM 
Quality Control (QC) Materials. Tha main feature of 
tha QA program is the use of matrix-baaed materials that are 
well characterized for TGDD concentration to ensure that the 
analytical system is in control. Human serum has been dis¬ 
pensed into vszious sized aliquots. Two of the pools have been 
spiked with various levels of dioxins and fciana, whereas tha 
other pool has not been spiked. Three pools of material are 
available to be inserted into the analytical run. The spiked 
poota contain the following riinvm. and furans in addition to 
those already present in human serum: 22,7,3-TCDD; 
1.2,3.4-TCQD, 1,2,3.7,8-pentachlorodibenzo-p-diorin 
(PnCDD): L2.1.7,3-PnCDD: L2,4.6.7.9-hezachlorodibenzo-o- 
dioxin (HxCDD); 1A33.7,9-HXCDD; lA3A7,3-HxCDb; 
u- 
J 
Figure 2. Quality comrol chart far spaced human serum pool L(TO^ 
samples). 
DL3.7,S.9-HxCDD: 123.4.7.3-HxCDD: L2.3.4.6.7>ianta- 
chlorodibenzo-p-dioxin (HpCDD): 12L3.4.6.7.3-HpCDlDt oc- 
tachlorodifaenzo-p-dioxin (OCDD): 2.3,7,3-tetrachifirodi- 
benzofuran (TCDF); octachlorodibenzofuran (OCDFiL 
QC Charts. QC Chans graphically document tha annhacal 
performance of the system. Figure 2 shows the QC dan for 
pool L. which was established during the development at this 
method: the statistical data are shown in Tabla IL 
Details of the Analytical Ron. The status of the spec¬ 
imens being analyzed is unknown to the laboratory easLysts. 
Samples are received and arranged in analytical tuna of five 
(three serum samples, a method blank, and one QC ample 
from pool I or L). In every fourth analytical run. a QCampie 
from a different pool is substituted for the pool I orLQC 
sample. In addition, a serum sample selected at randan from 
one of the four analytical runs will be analyzed in dtqaümce. 
providing that sufficient serum is available. The samples are 
then submitted for cleanup by a manual method (17) or an 
automated procedure (13) and then submitted to tin man 
spectrometary (MS) laboratory for analysis. Tha MS per¬ 
sonnel are also unaware of tha nature of the extract. 
To minima» tha possibility for carryover or croiwnnm. 
ination of samplea and analytical standards, analysa use 
separata syringes for samplea and for each analytical standard. 
Tha sample syringe is discarded periodically or when a mum 
sample that contains more than 75 ppq of 23.73-TCDD is 
analyzed. Between injections of a standard or a sample, the 
syringe is inserted through a Teflon-coated septum mao a 
15-mL vial containing 12 mL of toluene, ami tb. barrai ie oiled 
and emptied 10 times. This process is repeated twice more 
with different I5-mL vials containing toluene. A final wash 
of tha syringe is done by filling and emptying the bond 10 
times with a fourth toluene wash solution. These VWBU so¬ 
lutions are discarded at the end of each working day. Tha 
final 5 ML of toluene for reconstituting samples is then taken 
Table UL Validation of CDC Quantitation Stock Solution Against EPA and NBS Material for 2323-TCDD 
found* using CDC standard curve 
reported Conor* mean4 std dev coetf of vanaaon N % bias 
NBS* SRM 1614 67.3 i 23 69.4 3.0 42 4 +2.4 
EPA.* 737 ± 0.73 «f/ml» CAS: 17464)1-8 78.7 * 7.9 79.6 X7 3.4 4 +1.1 
CDC-A* X77 3J4 0.25 6.8 4 -u 
CDC-B* 5.02 4.46 0.23 52 4 -U 
CDC-C* 25.1 24.9 131 8.1 4 -0.8 
CDC-D* 502 49.4 4.23 3.6 4 -1.6 
CDC-E* 125.6 12X4 7.47 6.1 2 -L7 
‘Concentration in Pf/aL. ‘Each standard ns made in duplicata and each vial waa analyzed on two different days. 2400-og of (aCIIJ- 
Z5.7.3-TCDQ was added to each Vial as internal stanaard. After evaporation to dryness, tha viais were reconstituted to 50 wL with mane 
prior to mesa spectral anaivsia of 2 uL aliauota. * A 25-uL aliquot of iKi. standard waa added to each viaL •These standards were diluted 
LI00 before 2-uL aliquots wan taken. 'These standards ware préparée by an additional 1:10 dilution of tha stock solution used ta mass 
CDC-C. D. and E. Tha increased bias for these two standaroa may redact tha extra 1:10 dilution of the track solution required to peepers 
these two standards. 
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Tabla IV. Bacovariea af Incarnai Standard and Nairn Wj-TCDO "Spiked" Hunan Samis 
aliquot found (200-g samoias) 
added target* 1 2 3 4 meeaobed - hiaa. % 
A 49.8 is 5.1 - 42.0 ’ 39.0 32.0 64.2- 442*12.0 -IL0 
B 72.3 * 3.5 78.5* 65.5 74.0 80.9 74.7 * 5.9 +3.5 
C - 95.5 = 6.9 752 732 90.0 1122 87.9 * 15.6 -8.0 
[uCul-22,7,S-TCDD (% recovery) 
200-g samples of human serum spikad with 240 pg of [“Ci-j-TCDD 56. 50. 34. 93.48. 63. 81. 80. 66. 59. 78 
50-g samples of human serum spikad with 240 pg of (13CISJ-TCDD 58. 58. 63. 51. 64. 32 
10-g samples of human serum spikad with 240 pg of [UC|2J-TCDD 65. 68. 6L 54. 50.100, 77 
‘The target value waa calculated by adding calibrated aliquots to the pool I (x » 25.8 * 3.4 ppq). Aliquot A • 24.0 * 3.8 ppq (2V • 5); 3 
w 46.4 * 0.6 ppq (IV - 3); C • 69.7 * 6.0 ppq (N - 5). ‘Undetermined amount of sample spilled. The internal standard ion counts were 
low. 
from a fifth verified blank toluene source. The sup-by-step 
procedure leading to an analytical result, the accompanying 
documentation, and the criteria for identifying TCDD and 
for reporting results have been reported previously (17). 
EVALUATION AND VALIDATION STUDIES 
Interferences. We have previously described (17) our 
studies to verify the elimination, by the cleanup process, of 
compounds thac could interfere in the analysis for TCDDs. 
The results of these analyses indicated that these potentially 
interfering compounds, which are present at 101- to 10*-fold 
excess, are effectively removed during the multicolumn 
cleanup of the sample. 
Validation of 22.7,8-TCDD Analytical Standards. In 
a previous analysis of a series of 22.7,3-TCDD standards 
received from various laboratories and chemical suppliers, we 
found that the stocks varied from -65% to +35% of the stared 
concentration (17). Because of these findings, we validated 
our stock solution against 2J.73-TCDD that we had syn¬ 
thesized and characterized in our laboratory. At the time of 
the previous report, the National Bureau of Standards (NBS) 
had plans to issue a Certified Reference Material for 
2&7.S-TCDD, which is now available. Therefore, we have 
validated our stock standard solution that we used for our 
quantitative measurements against CDC synthetic material 
and EPA and NBS analytical standards. The results of the 
measurements are given in Table HL The agreement among 
these standards is very good and well within the stated un¬ 
certain! ty. 
Recovery of 22J3-TCDD. Human serum samples (200 
g, 50 g, 10 g) were spiked with 240 pg of [uC,J-23.7,8-TCDD 
and processed through the entire cleanup procedure described 
shove and the entire five-column cleanup described previously 
(17, 18). These samples were analyzed by using [nCl,]- 
2^,7.3-TCDD as the external standard to give average re¬ 
coveries of 69%, 54%. and 68%, respectively (Table IV). 
Recovery of the 22 TCDDs. A standard that contained 
the 22-TCDDa that had been processed through the five- 
column cleanup procedure was compared with a standard 
analyzed directly by GC/MS. The results, which ranged from 
95% to 124% recovery (17), were adequate for quantitating 
the 22 TCDDs. 
Within-Vial Variability. Periodically, we need to rerun 
the mass spectral analysis of S sample because of a number 
of possible hardware or software problems such as electrical 
failure in the laboratory, poor signal-to-noiae ratio, incorrect 
isotope ratios, high-voltage shut down, or data system crash. 
In addition, highly concentrated samples may sometimes 
saturate the detector and require dilution before a second 
analysis. We have examined the variability involved in a 
reanalvsis from a sample vial (2 uL of 3 uL) that was analyzed 
(2uLof 5 uL) the same day, one day eariian and up to 27 days 
Table V. Within-Vial Variability 
day 1 day l msrimum average 
sample pg (ppert Pg IPPtr) % bias % bias 
I 19.7 (L87) 182 079) 42 5.4 
2 19.8 087) 2L0 (123) 6.1 
3 14.7 (732)* 1 132 (672)* 84 
4 42 (2L3>* 1 44 (222)* 24 
day 1 day 2 maximum average 
P«(pptr) Pf (pptr) % bias % bias 
5 60.7(5.77) 39.7 (622) 14.7 5.7 
8 572 (5.49) 56.4 (5.40) L6 
7 712(3.45) 752(322) 5^ 
8 48.0 (123) 472 (121) LI 
9 78.0(125) 822(126) 54 
day 1 day5 to 18 maximum average 
pg (pptr) pg (pptr) % bias % bias 
10 122(642)* 07(58.71* 9.4 74 
U 62 (33.41* 6.4 (32.4)* 3.0 
12 52(282)* 52(25.7)* L9 
13 5.4 (272)* 42(232)* 16.4 
14 392 (182)* 40.4 (185)* 2.0 
IS 36.4 (5190)* 412 (5960)* 144 
day 1 day 27 maximum average 
PI (PPtri pg(ppw) % bias % bias 
16 132 0.75) 18.7 076) as 94 
17 18.6 077) 13.7 (120) 36 
18 382(125) 412 (128) 7 JO 
19 532 071) 512(124) 44 
20 732 (L79) 78.7 (122) L7 
* Perta-par-quaririllii 
Tabla VL Quantitation of Combined Aliquots of QC Pool L 
expected* 
X * ltd dav obad 
.apt lavaLg Pg (PPt> pg (ppt) % bias 
1 102 20.5 (123 * 029) 18.6 075) -9.1 
1023 202 (123 * 029) 182 077) -05 
21.06 40.6 (123) 382(125) -44 
3L45 60.7 (123) 532 (L71) -114 
42.14 812 (123) 752 079) -7.4 
2 . 2L113 402(123) 44.4 (20) +84 
3L795 6L4 (123) 592 087) -3.0 
.9 rteo 812 (123) 1052 (2.48) +206 
3 10225 202 (123 * 029) 210 (2.0) +34 
20284 402(123) 39.1 (126) -3.4 
31287 6L0 (L93) 690 (209) +134 
42052 SL4 (123) 632(20) +06 
' ‘See Table B for QC pool L data. 
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Tabla VTL Concentration of 23.74-TCDD in Hi 
Plum. Whole Blood, and Sonin Somplm 
conetntndoa 
poolad serum. whole lipid 
no. of persona sex race «n weight* weight* 
10 42.0 c 
11 29.0 c 
3 95 c 
3 21.0 c 
9 1222 c 
4 * c 
67 25.3 4.2 
78 29.5 c 
107 19.8 c 
d 19.6 c 
d 31.9 € 
d 10.9 e 
d 123 e 
t M W 23 14.0 c 
c F W 59 54.5 c 
# M W 27 48.0 c 
« F w 30 5L0 c 
« M B 51 26-5 c 
/ M w 582! 37.6 c 
f M w 26J3 535 m 
t P B 183 133 2.77 
t M w 49.9 63.0 3.7 
f M w 23.9 133 157 
f F B-' 40.9 34.6 4.88 
t M w 23.1 2L7 3.04 
t F B 33.6 39.1 5.74 
t F w 58^ 45.4 7.08 
t M w 58.0 83.1 12.0 
t M w 59.5 28.3 4.91. 
t M w 35.4 24.2 3.071 
f M w 70.0 211 28.0 
t F w 37.0 142 91 Q 
t F w 48.6 30.0 4.10 
. t F w 43.2 172! 4.93 
F w 63.6 58.3 9.43* 
t F w 37.4 45.3 11.94 
: f M w 45.2 22.0 4.44 
f F w 48.1 24.1 ± 99 
f F w 40.5 245 4.72 
f -F w 3L3 15.0 258 
■Concentration in ppq. * Concentration in pptr. 'Percent lipid 
not determined. à Plasma sample from 4 different individuals. 
* Whoio blood sample (lined ceils) from 5 different individuate, 
f Serum sample from 22 different individual!. 
earlier (Table V). The data in Tabla V indicate that the 
•amples may be reanalyzed up to a month later with less than 
a 10% bias being introduced. 
Method Performa pce All 200-g serum samples examined 
thus far have produced sufficiently strong signals ( signal-to- 
aoise ratio > 3/1) to permit quantification. With regular 
routine maintenance, a limit of quantification of 5 ppq for a 
200-g sample may be readily achieved for routine samplee from 
epidemiological atudiee. We have previously defined oat 
criteria (17) for reporting samplee such aa Q (quantifiables, 
NQ (nonqiianriffahla). and ND (nondetect). The accuracy of 
the method is demonstrated in part bÿ thé spiked recovery 
experiments (Table IV). In these tests, three different cali¬ 
brated aliquots of 2J.73-TCDD were spiked into séparas» 
200-g samples of pool I. This experiment was performed twice ' 
by tero different analysts. The values obtained on analysm 
are in good agreement with the expected values. We have aba 
conducted a series of experiments in which we combined vase 
of QC pool L to provide —20-, 30-, and 40-g samples th»t wenc 
spiked with 210 pg of [uCl2]-2.3.T,3-TCDD and carried 
through the analytical procedure. The expected and observed 
values (Table VI) are in good agreement. Another measure 
of system performance is the precision associated warn 
characterizing the QC materials (see Table II). For spiked 
10-g serum samples at the L9 pptr level, a coefficient of 
variation (CV) of 15% was observed. For 200-g unspiked 
serum samples at the 25.3-ppq level, a CV of 13% was ob¬ 
served. 
Stability of 23,7,8-TCDD in Human Serum. Samplee 
of QC pools I and L wen stored at -40 °C and analyzed at 
various times during the method development phase of this 
study. We have observed no apparent degradation of the 
23.7.8- TCDD in these materials over a period of 1 yean. 
RESULTS AND DISCUSSION 
Human Serum Results. During and after the method 
development phase of this study, we have successfully a»st- 
lyzed. for 23,7,8-TCDD, various individual samples of human 
serum, plasma, and whole blood, as well as pooled uunptrs 
collected from local and regional centers. These résulta, 
summarized in Tabla VU. an the first reported levels of 
2.3.7.8- TCDD in human serum taken from individuals in the 
general population with no known exposun to 23,73-TCDDL 
The arithmetic mean of the individual serum samples is 473 
ppq (range of 13.5-211 ppq, n » 22) on a whole-weight bams 
and 7.56 pptr (range of 1.87-26.0 pptr. n » 21) on a lipid- 
weight basis. These results in serum on a lipid-weight bass 
are in good agreement with results that we have published 
previously (11,15.17) relating to human adipose tissue, as 
well as with results in adipose tissue from other laboratosba 
(12,13,31-33) as shown in Table VHL 
Future Method Development. A key to substituting 
serum for the more difficult to obtain adipose specimen is ta 
experimentally calculate the partitioning coefficient of 
23.7.8- TCDD in these two matrices. Ws have begun a study 
of the distribution of 2J.73-TCDD in paired serum sad 
adipose tissue samplee collected from the same individuals. 
The analysis of each blood sample for total and free chole¬ 
sterol. triglycerides. HDL, and phospholipids will allow us ta 
«vamma the distribution of 23,7,3-TCDD in the various Igad 
compartments of hlood. 
Tabla VIII. Coneantnuoa of 13,7 J-TCDD in Human Seram anli Adi posa Tissue from Individuals with No Known TCDD 
Exposure 
present study: human scram on lipid-weight bests 
human adipose. Patterson at sL (14) 
human adipose. Patterson et ai. (15) 
human adipose. Graham at ai. (32) 
human adipose 
human adipose. Schectar et aL (12) 
N mean, pptr range, pptr 
21 7.6 13-26.0 
57 7.4 L4-20.2 
35 7.1* 2.7-L9 
35 7.2* 
61* 7.5 1-15 
25 6.4 ND/ 2.0-13 
8 7J2 L4-17.7 
* Geometric moan. * Combination of résulta from ref 13. 32. and 33. Three résulta from persons known to have had exposure to 2.V5- 
tnchloroohenoi were excluded. * ND. not detected. 
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Spatiotemporal Description of the Diffusion Layer with a 
Microelectrode Probe 
Boyce C. Engstrom.* Trevor Meaney, and Ray Tople 
Department of Chemistry, University of South Dakota, Vermillion, South Dakota 57069 
R. Mark Wightmaa 
Department of Chemistry, Indiana University, Bloomington, Indiana 47405 
Under typical electroanalytical conditions, concentrations 
of chemical species are perturbed from their bulk solution 
values at distances away from the electrode surface measured 
in tans of micrometers or less. While theories exist that 
describe interracial concentrations as a function of distance 
and time for a number of electroanalytical situations, the 
experimental observation of interfarisl concentrations has not 
been poesible due to the lack of ternniqm» with the necessary 
spatial and temporal resolution. To provide direct observation 
of concentration profiles relevant to electroanalytical chem¬ 
istry, the probe must provide spatial resolution in the mi¬ 
crometer range and temporal resolution approaching the 
millisecond range. In addition, the ideal probe would not 
perturb the interfacial concentrations from their normal 
profiles. 
Two approaches to interfacial chemical analysis meeting 
those requirements have been reported. Jan et aL (1.2) have 
O 19S7 Amancan OoMod Soculr 
Carbon fiber micro electrodes wars used to measure (ho mf- 
croscopicalty local concentration of chemical spades within 
(he diffusion layer of another electrode. Concentration prof (lee 
of ferricyadds were obtained at a platinum electrode during 
a double potential step experiment. On the forward step, 
reliable concentration pottles could be obtained at times as 
short as 20 ms after the potential step, when the diffusion 
layer thickness Is only 4 pm. On the reverse step, reliable 
profiles were obtained at times greater than 100 mm. The 
technique was used la study the electrochemistry at epi¬ 
nephrine. in which the oxidation product undergoes chemical 
transformation within the diffusion layer. Concentration pro¬ 
files at both the immadale electrochemical product and the 
chemical reaction product were obtained. Differentiation 
between two possible mechanisms was accomplished by 
comparing experimentally determined concentration profiles 
with profiles generated by tfgitai simulation. 
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